retatrutide triple agonist gip glp-1 glucagon phase 3 2025 From Obesity to Metabolic Health: Why Is a Game-Changer What Is Retatrutide? The Triple

This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides

In the search for novel treatment strategies for alcohol use disorder (AUD), glucagonlike peptide1 (GLP1) receptor agonists (GLP1RAs) approved for treating Type 2 diabetes and obesity have caught much attention

GLP-1 treatments are being found to provide health benefits beyond weight loss, which could drive sales

95% CI 0.90, 1.01) and cerebrovascular events (HR 0.99

Additionally, novel diagnostic tools, such as corneal confocal microscopy and biomarker-based tests, have improved early detection and intervention